Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Santhera: phase‑1 topline for AGAMREE® shows glucocorticoid activity without meaningful immunosuppression
Santhera reports topline results from a Phase‑1 study of AGAMREE® conducted by Catalyst, which show glucocorticoid and anti‑inflammatory effects at clinical doses but only minor immunosuppressive biomarker effects. Relevant immunosuppressive effects were observed only at doses above the currently approved AGAMREE dosage. Catalyst holds North American rights for DMD and potential follow‑on indications; Santhera retains pre‑negotiation rights outside North America and is entitled to sales‑based milestones and royalties. » More on finanzen.net
Santhera reports 98% revenue growth in 2025 driven by AGAMREE
Santhera recorded a 98% increase in total revenue in 2025 to CHF 77.4 million, driven by strong uptake of AGAMREE in Europe and the US as well as license and milestone receipts. Product sales rose to CHF 25.8 million and license and milestone payments to CHF 23.1 million; Catalyst paid a milestone of USD 12.5 million after US sales exceeded USD 100 million. After year-end, Santhera signed an exclusive license agreement with Nxera worth up to USD 205 million, which included an upfront payment of USD 40 million. Cash and cash equivalents amounted to CHF 22.4 million as of 31.12.2025 (excluding the Nxera upfront), and the company expects cash-flow break-even in Q3 2026 without additional financing. » More on finanzen.net
Santhera appoints Marc Clausse as chief commercial officer
Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO). Clausse will assume responsibility for leading the company’s commercial activities. » More on finanzen.net
Santhera closes $13m royalty agreement to support AGAMREE
Santhera has confirmed the closing of a $13 million royalty agreement announced in September with R-Bridge and the Partners Group. The agreement covers 25% of net royalties for AGAMREE from Catalyst in North America and from Sperogenix in China; payments are limited and will revert to Santhera after a cap or a set term is reached. Santhera retains a buyback right for the royalties and will use the funds to finance the global launch of AGAMREE. » More on finanzen.net
Santhera: long-term analysis confirms improved safety profile of AGAMREE in Duchenne muscular dystrophy
Santhera reports positive topline results from a long-term analysis of the ongoing, open-label, multicenter GUARDIAN study of AGAMREE (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The data confirm an improved safety profile for AGAMREE. Further details are set out in the full study. » More on finanzen.net
Financials
In the last quarter, Santhera Pharma Aktie had revenue of €52.36m and net profit of -€23.32m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 52.36m | - |
| Gross profit | 19.44m | - |
| Net profit | -23.32m | - |
| EBITDA | -4.16m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €215.78m |
Number of shares | 15.31m |
52-week high/low | €20.30 - €12.69 |
| Dividends | No |
Beta | -0.28 |
P/E ratio | -5.58 |
PEG ratio | -0.07 |
P/B ratio | -29.57 |
P/S ratio | 1.92 |
Company profile
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
| Name | Santhera Pharma Aktie |
| CEO | Orlando Oliveira |
| Headquarters | Pratteln,
bl Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 06/03/2014 |
| Employees | 78 |
Ticker symbols
| Exchange | Symbol |
|---|---|
SIX | SANN.SW |
London Stock Exchange | 0QN1.L |
Pnk | SPHDF |
London | 0QN1.L |